Biogen Idec's multiple sclerosis blockbuster Tecfidera for a second time has hit a roadblock in its effort to replicate in Europe the kind of runaway success it has had in the U.S. Germany's price watchdog IQWIG says it has found "no additional benefit" for the treatment compared to existing options, a preliminary decision that could deny it premium pricing there.
Germany is implementing a system that allows the authenticity of drugs to be checked at the pharmacy level to protect against counterfeits.
Having already bought the land on which Merck KGaA's salt plant in Lehrte, Germany, sits, salt maker Schüssler Novachem has now bought the production and laboratory equipment from the German drugmaker.
Novo Nordisk has decided to play ball in Germany. The Danish drugmaker now plans to launch its brand-new diabetes drug Tresiba in that country, despite a notorious pricing policy that Novo feared would interfere with its success.
Gilead Sciences has argued that its hep C blockbuster Sovaldi will save healthcare payers money by preventing transplants for patients who develop cancer. But now the U.S. drugmaker has run into the Germany's IQWiG, the toughest among Europe's drug price watchdogs, and it says the evidence for that claim is unclear.
German pharma giant Bayer got back-to-back bad news on two of its newest drugs, from two different countries, no less.
GlaxoSmithKline's asthma behemoth Advair may be losing ground in Europe, but a legal win may stop some of the bleeding--at least in Germany. The British pharma giant has obtained a preliminary injunction there to stop Novartis' Sandoz from hawking its generic, AirFluSal Forspiro, thanks to the inhaler's purple color.
The German drugmaker is feeling certain enough about a couple of potential hemophilia hits in its pipeline that it will spend nearly $700 million on new facilities in Germany that it says will add 500 jobs in its home country.
A pair of billionaire brothers helped Glycotope round up $76 million in venture cash to pay for Phase IIb trials of a pair of cancer drugs as well as a late-stage effort for a fertility therapy.
German med school deans aren't too concerned with pharma reps swaying their students' future prescription habits, according to a recent survey.